Division of Fujifilm Holdings Corp.
Latest From Fujifilm Corp.
As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.
Amid the ongoing spread of the coronavirus outbreak, China turns to novel and repurposed antiviral drugs but also courts traditional medicines to ease public fear over the largely unknown threat.
Diversified Japanese giant gains global rights to Cynata’s novel therapy for GvHD as part of continued push into cell and regenerative medicine, amid ongoing discussions between Sumitomo Dainippon and the Australian bioventure over a potential wider acquisition.
Deal Watch: Celgene Reworks Alliance With Jounce, Gaining Global Rights To Macrophage-Targeting Candidate
Revised agreement of 2016 collaboration returns all vopratelimab rights to Jounce. Gilead fortifies antiviral pipeline in deals with Novartis, Durect.
- Contract Research, Toxicology Testing-CRO
- Diagnostic Imaging Equipment & Supplies
- Generic Drugs
- Therapeutic Areas
- Pacific Rim
- Parent & Subsidiaries
- Fujifilm Holdings Corp.
- Senior Management
- Shigetaka Komori, Pres. & CEO
- Contact Info
Midtown West, 7-3, Akasaka 9-chome